Evidence map›Paper›PMID 34595847›Full record

ArticleArthritis care & research2023

Unique Serum Immune Phenotypes and Stratification of Oklahoma Native American Rheumatic Disease Patients.

Samantha Slight-Webb, Carla J Guthridge, Joseph Kheir, Hua Chen, Ly Tran, Tim Gross, Virginia Roberts, Sohail Khan, Michael Peercy, Bobby Saunkeah and 2 more

Abstract read
In one paragraph

Article in Arthritis care & research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Samantha Slight-WebbOklahoma Medical Research Foundation, Oklahoma City.
Carla J GuthridgeOklahoma Medical Research Foundation, Oklahoma City.
Joseph KheirOklahoma Medical Research Foundation, Oklahoma City.
Hua ChenOklahoma Medical Research Foundation, Oklahoma City.ORCID 0000-0002-0641-2837
Ly TranOklahoma Medical Research Foundation, Oklahoma City.
Tim GrossOklahoma Medical Research Foundation, Oklahoma City.
Virginia RobertsOklahoma Medical Research Foundation, Oklahoma City.
Sohail KhanCherokee Nation, Tahlequah, Oklahoma.
Michael PeercyChickasaw Nation, Ada, Oklahoma.
Bobby SaunkeahChickasaw Nation, Ada, Oklahoma.
Joel M GuthridgeOklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City.
Judith A JamesOklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City.ORCID 0000-0002-9574-7355

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI PAUL G SPICER · 2013 to 2026
$68.2M
Oklahoma Rheumatic Disease Research Cores Center (Overall Application)P30AR073750 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2018 to 2026
$8.5M
RAD-X UP NARCH Supplement: A Cherokee Nation Community-Driven Program for Testing and Contact Tracing (Cherokee PROTECT)S06GM127983 · NIGMS · CHEROKEE NATION · PI KHAN, SOHAIL IMRAN · 2018 to 2022
$6.4M
Oklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail SuccessUM1AI144292 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JUDITH A JAMES · 2019 to 2026
$3.3M
NIAID NIH HHS UM1 AI144292NIAMS NIH HHS P30 AR073750NIGMS NIH HHS S06 GM127983NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

objectiveNative American (NA) populations have higher rates of rheumatic disease and present with overlapping disease symptoms and nontraditional serologic features, thus presenting an urgent need for better biomarkers in NA diagnostics. This study used a machine learning approach to identify immune signatures that more effectively stratify NA patients with rheumatic disease.

methodsAdult NA patients with autoantibody-positive (AAB+) rheumatoid arthritis (RA; n = 28), autoantibody negative (AAB-) RA (n = 18), systemic autoimmune rheumatic disease (n = 28), arthralgia/osteoarthritis (n = 28), or polyarthritis/undifferentiated connective tissue disease (n = 28), and control patients (n = 28) provided serum samples for cytokine, chemokine, and AAB assessment. Random forest clustering and soluble mediator groups were used to identify patients and control patients with similar biologic signatures. The American College of Rheumatology criteria specific for systemic disease and RA identified differences in disease manifestations across clusters.

resultsSerum soluble mediators were not homogenous between different NA rheumatic disease diagnostic groups, reflecting the heterogeneity of autoimmune diseases. Clustering by serum biomarkers created 5 analogous immune phenotypes. Soluble mediators and pathways associated with chronic inflammation and involvement of the innate, B cell, T follicular helper cell, and interferon-associated pathways, along with regulatory signatures, distinguished the 5 immune signatures among patients. Select clinical features were associated with individual immune profiles. Patients with low inflammatory and higher regulatory signatures were more likely to have few clinical manifestations, whereas those with T cell pathway involvement had more arthritis.

conclusionSerum protein signatures distinguished NA patients with rheumatic disease into distinct immune subsets. Following these immune profiles over time may assist with earlier diagnoses and help guide more personalized treatment approaches.

Indexed as

Arthritis, RheumatoidRheumatic DiseasesAmerican Indian or Alaska NativeAutoantibodiesBiomarkersHumansOklahomaPhenotypeAutoantibodiesBiomarkers

Identifiers

PMID34595847
PMCPMC8971136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.